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目的：TIPE 及 TIPE2 是 TNFAIP8（Tumor necrosis factor-α induced protein-8，
TIPE，TNFAIP8）家族的重要成员，TIPE 是调控凋亡进程的重要分子，本研究
之一是应用 TIPE 不同表达的 BGC823 细胞株建立胃癌裸鼠移植瘤模型，观察
TIPE 对移植瘤生长的影响；同时收集并检测胃癌临床标本 TIPE 的表达特点，分




TIPE2 蛋白及 mRNA 水平表达特点，同时检测细胞因子的变化及免疫细胞的浸
润，分析三者之间的联系，探讨 TIPE2 在异种移植中的可能作用。 
方法：第一部分：利用实时荧光定量 PCR 法检测 16 例胃癌组织及癌旁正常
组织中 TIPE mRNA 的表达，分析不同组织 TIPE mRNA 的表达情况。结合临床
资料，分析 TIPE 在胃癌发生、发展以及浸润、转移的关系。 
第二部分：应用 TIPE 表达差异的 BGC823 细胞株，接种于裸鼠建立裸鼠
胃癌移植瘤模型，每天应用伊立替康治疗并测量裸鼠体重及肿瘤大小，治疗两周




时间不同分为 1 天组和 3 天组，通过 PCR 检测 TIPE2 在移植心、脾脏、淋巴结
中的表达，同时通过 ELISA 检测受体大鼠外周血里细胞因子的变化，HE 检测移
植心病理变化，分析三者间的联系。 
结果：胃癌组织 TIPE mRNA 的表达明显高于癌旁组织（P<0.05），两者差































































Objective: As is known, TIPE and TIPE2 are important members of TNFAIP8
（Tumor necrosis factor-α induced protein-8，TIPE，TNFAIP8） family. Since TIPE 
is a recently discovered antiapoptotic molecule, part of this study focuses on 
constructing a nude-mouse transplanted tumor model with the BGC823 cell 
strain--different expression of TIPE, and observing the influences TIPE has on the 
growth of the transplanted tumor, in the course of which expressions of TIPE in the 
clinical sample of gastric cancer are collected and detected so as to analyze their 
relationship with clinical pathological characteristics of gastric cancer, as well as to 
explore TIPE's relationship with gastric cancer biological behavior and to figure out 
its effects on the development of gastric cancer. 
TIPE2 is an immune negative regulator, which plays an important part in 
balancing immune status. Another part of this study deals with building a heart 
xenotransplantation model and collecting graft and spleen tissues at different time 
after transplantation so as to figure out the characteristics of TIPE2 protein and 
mRNA expression and the changes of cytokines, as well as to analyze their 
connections and to explore the possible functions of TIPE2 in the course of 
xenotransplantation.  
Method: Part 1: Q-PCR method was used to detect and analyze TIPE mRNA 
expressions in 16 cases of gastric cancer tissues and normal adjacent tissues. The 
results were combined with clinical pathological data to analyze the links between 
TIPE and gastric cancer occurrence and development. 
Part 2: By transplanting BGC823 cell strain with different TIPE expressions to 
the right armpit of nude mice, we constructed a nude-mouse transplanted tumor model. 
Weight of mice and tumor size were measured every day after treating the mice with 
irinotecan. After two weeks of treatment, the nude mice tumor was taken out for 
weighing. HE staining for the tumor tissue was performed to detect apoptosis and then 
analyze TIPE’s effects on the development of gastric cancer. 
Part 3: Experiments model were performed that hearts from hamsters were 
transplanted to Lewis rats recipients heterotopically. The experiments were divided 
into two groups: one with Leflunomide intervention for 3 days and another without 















depending on the different time of detection: one- day and three-day. PRC was used to 
detect the expressions of TIPE2 in the transplanted heart, spleen and lymph gland. 
ELISA was applied to detect the changes of cytokines in PB of Lewis rats recipients 
HE staining was performed to detect the pathologic changes of transplanted heart. 
Then data were collected to analyze the connections of the above three findings. 
Result: Part 1 Our test shows that TIPE mRNA was expressed more in gastric 
cancer tissue than in adjacent tissues (P<0.05), and the difference is so striking that it 
is of statistical significance. TIPE mRNA expression is related to lymphatic metastasis 
and TNM (P<0.05) but irrelevant to gender and age (P>0.05). 
Part 2 It was observed in vivo experiments that in terms of weight and size,  
nude-mouse transplanted tumor model treated with irinotecan after 14 days  
(0.012±0.002g，137.95±16.78mm3)was significantly smaller than tumor without 
treatment (0.021±0.003g，178.13±26.95mm3), which is of statistical significance. 
Part 3 The acute rejection of Leflunomide after transplantation can effectively 
reduce the infiltration of inflammatory cells and prolong the survival time of the 
xenograft. The expression of TIPE2 in graft was increased with the prolongation of 
graft survival time, and the difference was statistically significant (P<0.05).  
Conclusion: It is found that TIPE can promote the proliferation of gastric cancer 
cell, so interference of TIPE can obviously up-regulate the apoptosis index of cancer 
cells. It’s indicated that TIPE is likely to get involved with the gastric cancer 
occurrence and development. Therefore, TIPE gene in gastric cancer treatment may 
become a new target. 
The result that TIPE2 expression varies with the degree of immune rejection 
indicates that TIPE2 may be related to immunological rejection. This shows that 
further insight into the possible mechanism of the function of TIPE2 in the 
transplantation immunity will provide us with new strategies for immunosuppression. 
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今。学会规定：癌灶之最大径在 5mm 以下者称为“微小胃癌”，而 6～10mm者为
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